Verastem - VSTM Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VSTM shares.
View VSTM analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12 month price targets for Verastem's stock. Their VSTM share price forecasts range from $3.00 to $6.00. On average, they expect the company's stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 844.4% from the stock's current price.
View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts.

Verastem's stock was trading at $0.4025 at the beginning of the year. Since then, VSTM shares have increased by 11.8% and is now trading at $0.45.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our VSTM earnings forecast.

Verastem, Inc. (NASDAQ:VSTM) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.05.

11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Verastem's stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.87%), Jefferies Financial Group Inc. (0.78%), Millennium Management LLC (0.51%), Renaissance Technologies LLC (0.29%), Two Sigma Investments LP (0.26%) and Dimensional Fund Advisors LP (0.25%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins, Ra Capital Management, LP, Robert E Gagnon and Timothy J Barberich.
View institutional ownership trends.

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VSTM stock can currently be purchased for approximately $0.45.

Verastem (NASDAQ:VSTM) has a market capitalization of $90.31 million and generates $2.60 million in revenue each year. The biopharmaceutical company earns $-73,810,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The official website for the company is www.verastem.com. The biopharmaceutical company can be reached via phone at (781) 292-4200 or via email at bsullivan@verastem.com.